Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster Drugs

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Novo Nordisk lowers full-year profit guidance in new CEO's maiden quarter

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the ...

Novo Nordisk loses further ground in obesity market

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...

Novo Nordisk’s weight-loss drug Wegovy could soon have a new sales outlet in the U.S.

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Novo Nordisk Q3 sales in line with forecasts in new CEO's maiden quarter

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 11%, in line with ...

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

Bagsværd, 5 November, 2025 - Financial report for the period 1 January 2025 to 30 September 2025 Operating profit increased ...

Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...